Neither should your monitoring. The Octave MSDA Test provides actionable, quantifiable disease activity data from a single blood draw.
Standard tools tell part of the story. The Octave MSDA Test reveals what’s happening at the biological level, earlier and more often.
Bridging the gap
Patients report worsening symptoms but MRI is stable, or vice versa. Which signal do you trust?
Seeing activity sooner
MRI shows damage after it has already occurred. By the time lesions appear, irreversible neuroaxonal damage has happened.
Objective, quantifiable insight
Patient-reported symptoms and neurological exams don’t always correlate with underlying biological activity.
Monitoring between visits
What’s happening to disease activity in the months between appointments? Are current treatments working?
The Octave Multiple Sclerosis Disease Activity (MSDA) Test measures 18 serum protein biomarkers across 4 biological pathways — Immunomodulation, Neuroinflammation, Myelin Biology, and Neuroaxonal Integrity — to deliver a comprehensive Disease Activity Score (1–10).
This score provides objective, quantifiable data about what’s happening at the biological level, detecting upstream inflammatory and immune changes before they result in irreversible nerve damage. From a simple blood draw, prescribers get actionable insights to inform DMT decisions.
18
Serum protein biomarkers measured from a single blood draw
4
Biological pathways assessed for comprehensive disease view
1-10
Disease Activity Score with clear clinical interpretation
Clinically validated with demonstrated utility and real‑world impact on treatment decisions.
21x
Greater risk of ≥2 gadolinium-enhancing lesions with a high scores (7.5‑10) vs. low/moderate scores (1‑7)
1 in 5
time points led to a changed clinical decision after MSDA testing
69%
of the time, clinicians agreed longitudinal MSDA results influenced their decision-making
Peer-reviewed validation
Published in Clinical Immunology (2023), Nature Communications (2024), and MSJ-ETC (2025), with ongoing research
Real-world evidence
Validated in clinical practice across diverse MS patient populations
The MSDA Report provides a Disease Activity Score (Low 1–4, Moderate 4.5–7, High 7.5–10) with clear clinical interpretation and longitudinal tracking to monitor treatment response over time. Individual pathway scores provide additional insight into what’s driving disease activity.
1.0 - 4.0
Low
Low disease activity
4.5 - 7.0
Moderate
4.5x greater risk of ≥1 Gd+ lesion
7.5 - 10
High
21x greater risk of ≥2 Gd+ lesions
Use the MSDA Test to inform treatment decisions with objective data — and get started through a simple, accessible workflow.
Order the MSDA Test and send patients to any of 7,000+ Quest Diagnostics locations nationwide for the blood draw. Most patients pay $100 or less out-of-pocket, and the Octave Cares financial assistance program (FAP) offers prompt-pay discounts, interest-free payment plans, and a dedicated patient support team.
Inform DMT initiation, switching, and discontinuation decisions with objective baseline and longitudinal data when you need it most.
DMT Initiation
Longitudinal monitoring
Relapse assessment
Treatment optimization
De-escalation decisions
Discontinuation decisions
Order the test, point patients to financial assistance, get results.
Quest Diagnostics
7k+
Patient service centers nationwide for convenient access
Octave Cares
≤ $100
Most patients pay $100 or less out‑of‑pocket with financial assistance
RESULTS DELIVERY
7 days
Business days from sample receipt - a clear, actionable report delivered to the ordering prescriber
Access peer-reviewed publications, clinical use cases, and ongoing research in our Clinical Resource Center.
Peer-reviewed publications
Clinical use cases
Ongoing research
Sample MSDA report